HER2+ breast cancer patients with FcγRIIIa-158 V/V genotype exhibited a higher objective response rate (ORR) and a longer PFS in response to trastuzumab than patients with FcγRIIIa-158 F/V or F/F variants (50). Here, ERBB2 is linked to breast carcinoma.